AR038618A1 - IRINOTECAN CRYSTAL CHLORIDE HYDRAULIC POLYFORM FORM - Google Patents
IRINOTECAN CRYSTAL CHLORIDE HYDRAULIC POLYFORM FORMInfo
- Publication number
- AR038618A1 AR038618A1 ARP030100656A ARP030100656A AR038618A1 AR 038618 A1 AR038618 A1 AR 038618A1 AR P030100656 A ARP030100656 A AR P030100656A AR P030100656 A ARP030100656 A AR P030100656A AR 038618 A1 AR038618 A1 AR 038618A1
- Authority
- AR
- Argentina
- Prior art keywords
- polyform
- irinotecan
- hydraulic
- approximately
- chloride
- Prior art date
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title 1
- 229960004768 irinotecan Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 abstract 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Una forma polimórfica de clorhidrato de irinotecan cristalino de fórmula (1), caracterizada porque brinda un patrón de difracción de rayos X de polvo que comprende valores de ángulo 2 tetha de aproximadamente 9,15; aproximadamente 10,00; aproximadamente 11,80; aproximadamente 12,20; aproximadamente 13,00 y aproximadamente 13,40. Un procedimiento para preparar esta forma polimórfica, composiciones farmacéuticas que la contienen como ingrediente activo, y el empleo de la misma y de sus composiciones farmacéuticas como agente terapéutico.Claim 1: A polymorphic form of crystalline irinotecan hydrochloride of formula (1), characterized in that it provides a powder X-ray diffraction pattern comprising tetha angle 2 values of approximately 9.15; about 10.00; about 11.80; about 12.20; approximately 13.00 and approximately 13.40. A process for preparing this polymorphic form, pharmaceutical compositions containing it as an active ingredient, and the use thereof and its pharmaceutical compositions as a therapeutic agent.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36068402P | 2002-03-01 | 2002-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038618A1 true AR038618A1 (en) | 2005-01-19 |
Family
ID=27789001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100656A AR038618A1 (en) | 2002-03-01 | 2003-02-28 | IRINOTECAN CRYSTAL CHLORIDE HYDRAULIC POLYFORM FORM |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1487840B1 (en) |
| JP (1) | JP2005525367A (en) |
| KR (1) | KR20040091083A (en) |
| CN (1) | CN1276923C (en) |
| AR (1) | AR038618A1 (en) |
| AT (1) | ATE364610T1 (en) |
| AU (1) | AU2003215594A1 (en) |
| BR (1) | BR0308133A (en) |
| CA (1) | CA2477926A1 (en) |
| DE (1) | DE60314378T2 (en) |
| DK (1) | DK1487840T3 (en) |
| ES (1) | ES2287495T3 (en) |
| IL (1) | IL163820A0 (en) |
| MX (1) | MXPA04008484A (en) |
| NO (1) | NO20044138L (en) |
| NZ (1) | NZ534999A (en) |
| PE (1) | PE20030923A1 (en) |
| PL (1) | PL372318A1 (en) |
| PT (1) | PT1487840E (en) |
| RU (1) | RU2300535C2 (en) |
| TW (1) | TWI270374B (en) |
| WO (1) | WO2003074527A1 (en) |
| ZA (1) | ZA200406927B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ541990A (en) | 2003-02-25 | 2009-04-30 | Yakult Honsha Kk | Method for preparing polymorphism of irinotecan hydrochloride |
| ES2245891B1 (en) * | 2004-07-09 | 2006-11-16 | Clinmet S.L. | "METHOD FOR OBTAINING A UNIVERSAL EXCIPIENT FOR ORAL ADMINISTRATION OF PHARMACEUTICAL ACTIVE PRINCIPLES AND COMPOSITIONS OF EXCIPIENTS RESULTING FROM THE METHOD". |
| RS52585B (en) * | 2004-12-21 | 2013-04-30 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | STEREOSELECTIVE PROCEDURE AND CRYSTAL FORMS OF CAMPTOTECIN |
| CA2591081C (en) | 2005-02-07 | 2014-10-28 | Fermion Oy | Process for the manufacturing of 7-ethyl-10-hydroxy camptothecin |
| PL1928883T3 (en) * | 2005-02-08 | 2014-03-31 | Fermion Oy | Process for the preparation of irinotecan hydrochloride |
| WO2006084940A1 (en) | 2005-02-08 | 2006-08-17 | Fermion Oy | Process for producing [1,4'] bipiperidinyl-1'-carbonyl chloride or hydrochloride thereof |
| DE602006012871D1 (en) | 2005-09-20 | 2010-04-22 | Scinopharm Singapore Pte Ltd | NEW CRYSTAL FORMS OF IRINOTECAN HYDROCHLORIDE |
| CN101318964B (en) * | 2007-06-07 | 2010-12-15 | 上海迪赛诺医药发展有限公司 | Novel crystal system of irinotecan hydrochloride and preparation method thereof |
| FR2918279B1 (en) * | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | ANTITUMOR COMBINATIONS CONTAINING A VEGF INHIBITOR AGENT AND IRINOTECAN |
| IT1391757B1 (en) * | 2008-11-11 | 2012-01-27 | Antibioticos Spa | IRINOTECAN CRYSTALLINE CHLORIDRATE AND METHODS FOR ITS PREPARATION |
| CN101659667B (en) * | 2009-09-07 | 2011-11-02 | 重庆泰濠制药有限公司 | Method for purifying irinotecan hydrochloride |
| US8546573B2 (en) | 2009-11-18 | 2013-10-01 | Cadila Healthcare Limited | Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate |
| JO3283B1 (en) | 2011-04-26 | 2018-09-16 | Sanofi Sa | Composition including Afflipersept, Folinic Acid, 5- Fluorouracil (5- Fu) and Irenosetan (FOLFIRI) |
| CN102866126B (en) * | 2011-07-05 | 2016-03-23 | 重庆华邦制药有限公司 | A kind of method of crystal form ratio in quantitative measurement compound |
| CN102311443B (en) * | 2011-08-24 | 2014-07-16 | 上海北卡医药技术有限公司 | Novel crystal form of irinotecan hydrochloride and preparation method thereof |
| RU2529831C2 (en) * | 2012-11-30 | 2014-09-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) | Method of treating colon cancer |
| RS58957B1 (en) | 2014-07-18 | 2019-08-30 | Sanofi Sa | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
| KR102293907B1 (en) * | 2015-06-30 | 2021-08-26 | 한미약품 주식회사 | Solid formulation for for oral administration containing irinotecan and a process for the preparation thereof |
| KR102066402B1 (en) * | 2017-12-22 | 2020-01-15 | 대화제약 주식회사 | Pharmaceutical composition for oral administration comprising irinotecan or its pharmaceutically acceptable salt |
| US10919905B2 (en) * | 2019-05-16 | 2021-02-16 | Scinopharm Taiwan, Ltd. | Polymorphism for irinotecan free base |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019790A (en) * | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | Novel camptothecin derivative |
| IT1282673B1 (en) * | 1996-02-23 | 1998-03-31 | Ist Naz Stud Cura Dei Tumori | CAMPTOTECIN DERIVATIVES AND THEIR USE AS ANTI-CANCER AGENTS |
| GB9918885D0 (en) * | 1999-08-10 | 1999-10-13 | Pharmacia & Upjohn Spa | Pharmaceutical formulations in hydroxypropymethycellulose capsules |
-
2003
- 2003-02-26 JP JP2003572995A patent/JP2005525367A/en not_active Withdrawn
- 2003-02-26 AT AT03743335T patent/ATE364610T1/en not_active IP Right Cessation
- 2003-02-26 NZ NZ534999A patent/NZ534999A/en unknown
- 2003-02-26 CA CA002477926A patent/CA2477926A1/en not_active Abandoned
- 2003-02-26 BR BR0308133-8A patent/BR0308133A/en not_active IP Right Cessation
- 2003-02-26 IL IL16382003A patent/IL163820A0/en unknown
- 2003-02-26 RU RU2004129307/04A patent/RU2300535C2/en not_active IP Right Cessation
- 2003-02-26 PL PL03372318A patent/PL372318A1/en not_active Application Discontinuation
- 2003-02-26 EP EP03743335A patent/EP1487840B1/en not_active Expired - Lifetime
- 2003-02-26 ES ES03743335T patent/ES2287495T3/en not_active Expired - Lifetime
- 2003-02-26 KR KR10-2004-7013621A patent/KR20040091083A/en not_active Withdrawn
- 2003-02-26 DE DE60314378T patent/DE60314378T2/en not_active Expired - Fee Related
- 2003-02-26 DK DK03743335T patent/DK1487840T3/en active
- 2003-02-26 WO PCT/EP2003/001948 patent/WO2003074527A1/en not_active Ceased
- 2003-02-26 CN CNB038072726A patent/CN1276923C/en not_active Expired - Fee Related
- 2003-02-26 PT PT03743335T patent/PT1487840E/en unknown
- 2003-02-26 AU AU2003215594A patent/AU2003215594A1/en not_active Abandoned
- 2003-02-26 MX MXPA04008484A patent/MXPA04008484A/en not_active Application Discontinuation
- 2003-02-27 TW TW092104194A patent/TWI270374B/en not_active IP Right Cessation
- 2003-02-28 AR ARP030100656A patent/AR038618A1/en unknown
- 2003-02-28 PE PE2003000196A patent/PE20030923A1/en not_active Application Discontinuation
-
2004
- 2004-08-31 ZA ZA200406927A patent/ZA200406927B/en unknown
- 2004-09-29 NO NO20044138A patent/NO20044138L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL163820A0 (en) | 2005-12-18 |
| TW200303753A (en) | 2003-09-16 |
| EP1487840B1 (en) | 2007-06-13 |
| BR0308133A (en) | 2005-01-04 |
| CN1642958A (en) | 2005-07-20 |
| CN1276923C (en) | 2006-09-27 |
| RU2004129307A (en) | 2005-04-10 |
| ZA200406927B (en) | 2006-06-28 |
| ATE364610T1 (en) | 2007-07-15 |
| PL372318A1 (en) | 2005-07-11 |
| JP2005525367A (en) | 2005-08-25 |
| RU2300535C2 (en) | 2007-06-10 |
| CA2477926A1 (en) | 2003-09-12 |
| AU2003215594A1 (en) | 2003-09-16 |
| ES2287495T3 (en) | 2007-12-16 |
| NO20044138L (en) | 2004-11-29 |
| DK1487840T3 (en) | 2007-07-16 |
| KR20040091083A (en) | 2004-10-27 |
| PE20030923A1 (en) | 2003-10-29 |
| EP1487840A1 (en) | 2004-12-22 |
| MXPA04008484A (en) | 2004-12-06 |
| NZ534999A (en) | 2007-03-30 |
| DE60314378D1 (en) | 2007-07-26 |
| WO2003074527A1 (en) | 2003-09-12 |
| PT1487840E (en) | 2007-09-11 |
| DE60314378T2 (en) | 2008-02-28 |
| TWI270374B (en) | 2007-01-11 |
| HK1075044A1 (en) | 2005-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038618A1 (en) | IRINOTECAN CRYSTAL CHLORIDE HYDRAULIC POLYFORM FORM | |
| DE602004024375D1 (en) | carboxamide | |
| MXPA05007609A (en) | CaSR ANTAGONIST. | |
| ECSP055582A (en) | BENZOTIAZOL DERIVATIVES THAT HAVE BETA-2-ADRENORRECEPTOR AGONIST ACTIVITY | |
| SE0202539D0 (en) | Compounds | |
| SE9903760D0 (en) | New compounds | |
| CY1109728T1 (en) | New Hydantoin Derivatives for the Treatment of Foam Respiratory Diseases | |
| NO20073959L (en) | Quinazoline derivative, method of preparation and use thereof for inhibiting cancer cell growth | |
| AR029403A1 (en) | N-SUBSTITUTED DERIVATIVES OF CARBAMOILOXIALQUIL-AZOLIO, A PROCESS FOR ITS MANUFACTURE, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF A MEDICINAL PRODUCT | |
| GB0222514D0 (en) | Organic compounds | |
| TW200508207A (en) | New benzimidazole derivatives | |
| DE602005007339D1 (en) | NEBIVOLOL AND ITS NON-PHARMACEUTICAL SALTS, METHOD OF MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS OF NEBIVOLOL | |
| SA519401614B1 (en) | Novel naphthyridinone derivatives and their use in the treatment of arrhythmia | |
| PH12019500328A1 (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| MY140630A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| SE9903997D0 (en) | New compounds | |
| TW200504029A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| TW200639156A (en) | New compounds | |
| MY207759A (en) | Pharmaceutical drug containing heterocyclidene acetamide derivative | |
| SE0401763D0 (en) | Compounds | |
| SE0401655D0 (en) | New compounds | |
| SE0002729D0 (en) | Novel compound form | |
| MXPA05010783A (en) | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues. | |
| TW200517146A (en) | Novel composition | |
| TW200510370A (en) | Urea derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |